An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic Syndromes
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate that epoetin alfa works better than placebo in
improving anemia in patients with lower-risk myelodysplastic syndromes (MDS). The safety of
epoetin alfa will also be evaluated.